M Mesa-Guzmán1, J González2, A B Alcaide2, J Bertó2, J P de-Torres2, A Campo2, L M Seijo3, M M Ocón2, J C Pueyo4, G Bastarrika4, M D Lozano5, R Pío6, L M Montuenga7, M García-Granero8, J Zulueta9. 1. Departamento de Cirugía Torácica, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: mmesag@unav.es. 2. Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, Spain. 3. Departamento de Neumología, Clínica Universidad de Navarra, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 4. Departamento de Radiología, Clínica Universidad de Navarra, Pamplona, Spain. 5. Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 6. Centro de Investigación de Medicina Aplicada - CIMA, Universidad de Navarra, Pamplona, Spain; Departamento de Bioquímica y Genética, Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 7. Centro de Investigación de Medicina Aplicada - CIMA, Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 8. Departamento de Bioquímica y Genética, Universidad de Navarra, Pamplona, Spain. 9. Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Abstract
OBJECTIVE: Lung cancer (LC) is the leading cause of death from cancer worldwide. More than 27,000 LCs are diagnosed annually in Spain, and most are unresectable. Early detection and treatment reduce LC mortality. This study describes surgical outcomes in a longstanding LC screening cohort in Spain. METHODS: We conducted a retrospective study of surgical outcomes in a LC screening (LCS) program using low dose computed tomography (LDCT) since the year 2000. A descriptive analysis of clinical and radiological parameters, presence or absence of a preoperative diagnosis, pathological staging, morbidity, mortality, and survival was performed. RESULTS: Ninety-seven (2.5%) LC were diagnosed in 3825 screened. Twenty individuals with LC had no surgery due to advanced stage or small cell histology. Eighty-seven surgical procedures were carried out for suspected or biopsy proven LC, detected by LDCT. Most operated patients were male (57[85%]) aged 64±9.1 years. Nine patients underwent a second operation for a metachronous primary lung cancer. Mean tumor size was 15.2±7.6mm. Eight nodules were benign (9.2%). Lobectomy was performed in 56 cases (83.6%). Adenocarcinoma (n=39; 58.2%) was the most frequent histological type followed by squamous cell carcinoma (n=17; 25.4%). Fifty-nine (88%) tumors were in Stage I. Thirteen patients (15.4%) had 16 complications. The estimated survival rates at 5 and 10 years for stage I were 93% (95% CI: 79%-98%) and 83% (95% CI: 65%-92%), respectively. CONCLUSION: Lung cancer screening was associated with excellent surgical outcomes with 5 and 10-year survival rates exceeding 90 and 80%, respectively.
OBJECTIVE:Lung cancer (LC) is the leading cause of death from cancer worldwide. More than 27,000 LCs are diagnosed annually in Spain, and most are unresectable. Early detection and treatment reduce LC mortality. This study describes surgical outcomes in a longstanding LC screening cohort in Spain. METHODS: We conducted a retrospective study of surgical outcomes in a LC screening (LCS) program using low dose computed tomography (LDCT) since the year 2000. A descriptive analysis of clinical and radiological parameters, presence or absence of a preoperative diagnosis, pathological staging, morbidity, mortality, and survival was performed. RESULTS: Ninety-seven (2.5%) LC were diagnosed in 3825 screened. Twenty individuals with LC had no surgery due to advanced stage or small cell histology. Eighty-seven surgical procedures were carried out for suspected or biopsy proven LC, detected by LDCT. Most operated patients were male (57[85%]) aged 64±9.1 years. Nine patients underwent a second operation for a metachronous primary lung cancer. Mean tumor size was 15.2±7.6mm. Eight nodules were benign (9.2%). Lobectomy was performed in 56 cases (83.6%). Adenocarcinoma (n=39; 58.2%) was the most frequent histological type followed by squamous cell carcinoma (n=17; 25.4%). Fifty-nine (88%) tumors were in Stage I. Thirteen patients (15.4%) had 16 complications. The estimated survival rates at 5 and 10 years for stage I were 93% (95% CI: 79%-98%) and 83% (95% CI: 65%-92%), respectively. CONCLUSION:Lung cancer screening was associated with excellent surgical outcomes with 5 and 10-year survival rates exceeding 90 and 80%, respectively.
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333
Authors: María Rodríguez; Daniel Ajona; Luis M Seijo; Julián Sanz; Karmele Valencia; Jesús Corral; Miguel Mesa-Guzmán; Rubén Pío; Alfonso Calvo; María D Lozano; Javier J Zulueta; Luis M Montuenga Journal: Transl Lung Cancer Res Date: 2021-02